Agios Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was €1,025.02 Mil.
During the past 12 months, Agios Pharmaceuticals's average Total Assets Growth Rate was 61.80% per year.
During the past 3 years, the average Total Assets Growth Rate was -0.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 9.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 16.90% per year.
During the past 13 years, Agios Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 125.10%. The lowest was -17.00%. And the median was 18.90%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Agios Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Agios Pharmaceuticals Total Assets Related Terms
Agios Pharmaceuticals Total Assets Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Agios Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (FRA:8AP) has a Total Assets of €1,025.02 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Total Assets too high?
Agios Pharmaceuticals' current Total Assets is €1,025.02 Mil. Overall, Agios Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Total Assets compare to ABCL and KOD?
Agios Pharmaceuticals' Total Assets of €1,025.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Total Assets is €1,025.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (FRA:8AP) has a current Total Assets of €1,025.02 Mil. The stock's GF Value™ is €75.15, compared to a current price of €33.20 — trading 55.8% below its estimated fair value. The current Total Assets is €1,025.02 Mil. Agios Pharmaceuticals' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Total Assets is €1,025.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of €33.20 is trading 55.8% below its estimated GF Value™ of €75.15.
Key valuation signals for FRA:8AP:
Total Assets: €1,025.02 Mil
GF Value™: €75.15 vs. price of €33.20 (55.8% below fair value)
No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
46GF Score
Get the complete analysis for FRA:8AP
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8AP has been successfully added to your 
